Arcus Biosciences (RCUS) Scheduled to Post Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is set to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect Arcus Biosciences to post earnings of ($0.97) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.01. The firm had revenue of $31.00 million for the quarter, compared to analysts’ expectations of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The company’s quarterly revenue was down 8.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.93) EPS. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences Stock Up 1.6 %

Shares of Arcus Biosciences stock opened at $15.95 on Tuesday. Arcus Biosciences has a 12 month low of $12.95 and a 12 month high of $25.47. The business has a fifty day simple moving average of $17.18 and a 200-day simple moving average of $16.59.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, COO Jennifer Jarrett sold 24,555 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $20.07, for a total value of $492,818.85. Following the completion of the sale, the chief operating officer now directly owns 274,323 shares of the company’s stock, valued at $5,505,662.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, President Juan C. Jaen sold 3,900 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the transaction, the president now owns 1,211,365 shares of the company’s stock, valued at approximately $24,299,981.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Jennifer Jarrett sold 24,555 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $20.07, for a total value of $492,818.85. Following the completion of the transaction, the chief operating officer now directly owns 274,323 shares in the company, valued at $5,505,662.61. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,455 shares of company stock valued at $1,014,779. 12.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have weighed in on RCUS. Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Arcus Biosciences in a research note on Monday, March 25th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Arcus Biosciences in a research report on Thursday, February 22nd. Finally, Mizuho cut their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.25.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.